C
CMND
Clearmind Medici
5.84
-0.16-2.67%After Hours: 5.70 -0.14 -2.40%17:30 10/06 EDT
OPEN/PREV CLOSE5.89/6.00
TODAY RANGE5.70-6.17
VOL35.36K
MARKET CAP2.46M
52 WEEK RANGE5.25-3,840.00
AVG VOL (3M)84.98K
% TURNOVER8.11%
TURNOVER--
P/E (TTM)-0.0016
% RANGE7.89%
EPS(TTM)-3,613.4212
P/E(FORWARD)--
P/B0.0121
BVPS482.88
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP2.46M
SHARES OUTSTANDING420.88K
NEXT EARNINGS--
FREE FLOAT420.71K
LOT SIZE1
EX-DATE10/05/2026
News
Press Releases
Financial Reports
Profile
TipRanks·09/24 14:30
Psychedelic: Optimi completes psilocybin production for Phase 2 trial
TipRanks·09/23 12:46
SciSparc expands U.S. IP portfolio in collaboration with Clearmind Medicine
TipRanks·09/23 12:05
Clearmind Medicine announces publication in U.S. of 3 patent applications
NASDAQ·09/17 18:28
Biotech Stocks In Focus: Aethlon, Tiziana, Capricor, Firefly & Clearmind
NASDAQ·09/17 13:58
Clearmind Medicine Briefs FDA On Patient Access At Psychedelic Hearing
TipRanks·09/17 13:55
Psychedelic: Definium’s LSD-based drug meets endpoints in GAD study
TipRanks·09/17 13:06
Morning Movers: Yeti gains after issuing guidance at investor day
TipRanks·09/17 11:50
Clearmind Medicine briefs FDA following psychedelic hearing in Washington D.C.
TipRanks·09/11 12:20
Clearmind Medicine enrolls first patients with AUD in CMND-100 trial
Seeking Alpha·09/10 20:19
Clearmind Medicine Inc. GAAP EPS of -$0.57
TipRanks·09/10 14:50
Psychedelic: Optimi to initiate Phase 2 trial of psilocybin-assisted therapy
Same Industry
Name/Symbol
Change%
Price